AnBogen Therapeutics, Inc.

TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in a global Phase II trial. Under the terms of the agreement, BeiGene will supply tislelizumab to Anbogen for the study. In 2020, over 1.9 million new cases of colorectal cancer were diagnosed globally. Immune checkpoint inhibitors (ICIs) have emerged as a primary treatment for metastatic colorectal cancer (mCRC) with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). However, this innovative therapy benefits only a small fraction of patients, as less than 5% of mCRC cases exhibit dMMR/MSI-H. Consequently, there remains a significant unmet need for the 95% of patients with pMMR/MSS tumors, who do not respond to ICIs. ABT-301, a novel HDAC inhibitor, has shown promising safety and pharmacokinetic profiles in a prior Phase 1 study as a single agent. Preclinical studies indicate that ABT-301 enhances the effectiveness of anti-PD-1/anti-PD-L1 therapies by increasing CD8+ cytotoxic T cells and decreasing monocytic myeloid-derived suppressor cells within both the tumor and circulation, and inhibiting angiogenesis. These immune response enhancements may broaden the efficacy of ICIs in colorectal cancer patients. The upcoming Phase II study will investigate the effectiveness of treatment regimens combining ABT-301 and tislelizumab, with and without Bevacizumab, in pMMR/MSS mCRC patients with significant unmet needs. "We are excited to partner with BeiGene to investigate this promising combination therapy," said John Hsu, CEO of Anbogen. "ABT-301 has shown potential in preclinical studies, and we believe that combining it with tislelizumab could provide a new therapeutic option for patients with colorectal cancer." The clinical trial will be conducted in multiple centers and will evaluate the safety, tolerability, and preliminary efficacy of the combination therapy in patients with advanced MSS CRC. The study is expected to begin enrollment in the first quarter of 2025. About Anbogen Anbogen is a clinical-stage biotech company that completed a US$20M Series A in 2024. We are dedicated to developing precision anti-cancer drugs and are committed to R&D innovations to improve the lives of cancer patients around the world. The company was founded by Dr. Joe Shih in response to national science and technology policy. The team has years of experience in new drug development while working at the National Health Research Institutes and in the biopharma industry. Currently, there are two clinical-stage assets being developed. ABT-101 is being investigated in non-small cell lung cancer (NSCLC) patients who harbor HER2 exon20 insertion mutations, and ABT-301 and being investigated in pMMR/MSS mCRC patients in combination with anti-PD-1. For more information, please visit . SOURCE Anbogen Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024年7月已经接近尾声。根据即刻药数数据库，7月（截至7月28日）在中国生物制药领域至少有13家公司完成了新一轮融资。这些获得融资的公司的技术和管线涉及siRNA、反义寡核苷酸（ASO）等核酸药物；基于成纤维细胞的细胞治疗药物、基于多能干细胞的细胞治疗药物、诱导神经干细胞（iNSC）等细胞疗法；以及小分子靶向治疗药物、疫苗、活菌药物等领域，涵盖多种癌症，代谢性疾病、神经系统疾病以及罕见病等。本文将基于公开信息介绍其中10家致力于创新药研发的新锐公司。 公司：宝济药业 融资轮次：C轮 融资金额：数亿元 7月19日消息，宝济药业宣布完成数亿元人民币的C轮融资，由上海生物医药基金领投，上海科创集团、宝山国投集团及原股东晟德大药厂等跟投。宝济药业成立于2019年，专注于“合成生物学”技术平台的创新药研发。 根据宝济药业新闻稿介绍，该公司管线包括：1）皮下输注的重组人透明质酸酶，已递交中国NMPA药品注册上市许可申请并获受理；2）重组人卵泡刺激素-CTP融合蛋白，一周一针的长效促卵泡刺激素，用于辅助生殖领域，已向中国NMPA递交上市许可申请并获受理；3）重组免疫球蛋白降解酶，第二代IgG降解酶（低免疫原性），可应用于器官移植、因自身抗体导致的“百种”以上急性自身免疫性疾病、基因治疗前的预存抗体清扫等领域，即将进入中国临床3期研究。 公司：大睿生物 融资轮次：A+轮 融资金额：3500万美元 7月19日消息，大睿生物（Rona Therapeutics）宣布完成A+轮3500万美元融资。该轮融资由LongRiver江远投资领投，参与投资方包括昭德投资、博远资本、中启资本和礼来亚洲基金等。大睿生物致力于研发核酸创新药，用于代谢性疾病和中枢神经退行性疾病的治疗，本轮融资将用于推动创新的siRNA代谢管线项目进入全球开发，并扩展夯实中枢神经系统及其他领域的肝外递送平台。 大睿生物正在推进基于新一代siRNA平台生成的siRNA管线项目，首个RN0191管线PCSK9 siRNA项目已完成澳大利亚和中国的1期临床研究，正在推进高胆固醇血症的2期临床开发；针对APOC3基因的双链小干扰RNA（siRNA）药物RN0361也于近日在澳大利亚获批1期临床研究，旨在评估在甘油三酯升高的成人受试者中皮下给药的安全性、耐受性、药代动力学和药效学效应。 公司：夏同生物 融资金额：未披露 7月19日，夏同生物宣布获得知名上市公司旗下基金投资，用于加速神经脱髓鞘疾病等管线的研究者发起的临床试验（IIT）以及新药临床试验申请（IND）。夏同生物成立于2022年，专注于以细胞重编程及诱导分化技术开发少突胶质前体细胞（OPC）治疗神经系统疾病。 据新闻稿介绍，夏同生物证明了外源OPC在体内可形成髓鞘，并且建立了商业化人源OPC体外工业级制备技术，同时创造了以PBMC为起始细胞，经转录因子及小分子诱导重编程一步生成诱导神经干细胞（iNSC）的方法，使细胞来源丰富不受限制，且全过程不涉及胚胎干细胞。该公司计划以OPC治疗髓鞘形成低下性脑白质发育不良和多发性硬化等疾病。 公司：浩博医药 融资轮次：A轮 融资金额：3700万美元 7月15日，浩博医药宣布完成3700万美元A轮融资，本轮融资由信达生物主导发起设立的美元基金InnoPinnacle Fund追加领投，元生创投、汉康资本、启明创投、元生资本共同参与。浩博医药关注于HBV慢性乙肝功能性治愈和针对肝脏疾病的高效靶向治疗，并拓展了对肝脏以外新靶点的靶向小核酸治疗。该公司研发的具有乙肝“功能性治愈“潜力的裸露反义寡核苷酸（ASO）药物AHB-137注射液近日被中国NMPA纳入突破性治疗品种。 公司：椎元医学 融资轮次：天使轮 融资金额：数千万元 7月12日消息，椎元医学公司宣布完成数千万元的天使轮融资。本轮投资由凯利泰医疗和张江生命健康产业孵化天使基金（“张科禾苗基金”）共同领投，华医资本跟投。椎元医学是基于成纤维细胞开发创新细胞疗法的初创企业。根据新闻稿，所募资金将主要用于公司针对腰椎间盘退变的细胞治疗产品开发等。 椎元医学的核心管线FibroCell人成纤维细胞注射液是一款通过诱导退变髓核细胞向纤维细胞转化，从而管理椎间盘退变的细胞药物，已完成多个剂量组的IIT研究。相比目前的治疗手段，该疗法针对早中期椎间盘退变的患者有明确的临床价值。 公司：普康生物 融资轮次：对外融资 融资金额：1亿元 7月12日，普康生物宣布完成对外融资，引入岩山科技作为财务投资者，融资1亿元。该公司前身创立于1991年，主要产品为冻干甲型肝炎减毒活疫苗。2021年，普康生物完成股权调整、开启二次创业，选取具有良好技术积淀、确定性较高的管线推进产业化开发，其中人用狂犬病疫苗（人二倍体细胞）已进入临床3期试验阶段，甲肝灭活疫苗已进入pre-IND阶段，细胞基质流感疫苗已完成相关细胞和毒种工艺的技术验证；同时，该公司还投入科研力量开展重组蛋白疫苗、病毒载体疫苗的研究，搭建相关技术平台。 公司：跃赛生物 融资轮次：A+轮 融资金额：数千万元 7月11日，跃赛生物宣布，自今年4月获得A轮超亿元融资后，公司再获数千万A+轮融资。本轮融资由国科创投参与，融资资金将主要用于推进公司在干细胞治疗领域的创新管线以及加速临床转化。 跃赛生物成立于2021年，致力于开发新一代基于人多能干细胞技术的细胞治疗药物。根据跃赛生物官网资料，该公司现已开发多条产品管线，包括中脑多巴胺能神经前体细胞、GABA能神经前体细胞、GABA中间能神经前体细胞、脊髓神经前体细胞等，涉及帕金森病、缺氧缺血性脑病、癫痫、脊髓损伤等适应症。 公司：安天圣施 融资轮次：A轮 融资金额：近亿元 7月3日消息，安天圣施宣布完成近亿元A轮融资，由国投创业领投，原股东和瑞创投SCA3产业基金跟投。本轮所募资金将用于加速推进针对杜氏肌营养不良（DMD）及脊髓小脑性共济失调3型（SCA3）等适应症的产品研发。 安天圣施成立于2017年，专注于开发针对RNA剪接的反义寡核苷酸（ASO）创新药物。该公司目前已有多个在研产品管线，并在临床前研究中取得了较好的动物实验数据。针对DMD的产品与对照药物相比，蛋白表达水平提高10倍以上；针对SCA3的产品也已经开展IIT研究。此外，安天圣施还在持续扩展新技术在肿瘤和脊髓性肌肉萎缩症（SMA）开发中的应用。 公司：慕恩生物 融资轮次：C+轮 融资金额：3亿元 7月1日消息，慕恩生物宣布已于近日完成了3亿元C+轮融资，由国投聚力独家投资。慕恩生物是一家专注于微生物发掘与生物制造的生物技术公司。在生物医药板块，慕恩生物目前已有3项临床在研阶段药物与多个临床前药物管线研发，涵盖肿瘤、肥胖、2型糖尿病、非酒精性脂肪性肝炎等多项治疗领域。 慕恩生物自主研发的创新型活菌生物药MNC-168肠溶胶囊目前正在开展1期临床研究。这是一款肿瘤活菌药物，通过长期作用于肠道粘膜微环境，重新激活免疫系统的抗肿瘤能力，从而达到治疗多种恶性实体瘤的目的。MNO-863是慕恩生物自主研发的创新减肥活菌药物，适用于减肥/代谢综合征。临床前数据显示，MNO-863单药干预四周即可降低近10%的体重；与GLP-1R激动剂减肥药物联用后，具有平均超过20%的减重效果。 公司：安邦生技 融资轮次：A+轮 融资金额：2.2亿台币 7月1日消息，安邦生技（Anbogen Therapeutics）宣布成功完成A+轮募资，募集到2.2亿台币。这次募资是接续在2024年2月完成的3.8亿台币A轮募资，两轮合并共募集6亿台币。这轮融资由凯基创投（KGI Venture Capital）领投，并得到了现有投资者和新投资者的积极参与。 安邦生技是一家开发精准抗癌药物的临床阶段生物科技公司。该公司在研产品中，ABT-101为口服EGFR/HER2酪氨酸激酶抑制剂（TKI），首个适应症为HER2 exon20基因突变引发的非小细胞肺癌；ABT-301为一款HDAC抑制剂，首个适应症为转移型大肠直肠癌，目前皆已进入人体临床试验阶段；ABT-202为一款KRAS G12D抑制剂，目前处于临床前研究阶段。根据安邦生技新闻稿介绍，本次A+轮募资的资金将主要用于支持ABT-301与PD-1抑制剂联合治疗微卫星稳定（MSS）转移性大肠直肠癌的临床2期试验。 除了以上10家公司，7月份还有多家公司也宣布了融资消息，例如绿叶制药、晶核生物、英诺迈博等等。希望在资本的助力下，这些生物医药公司可以加快候选药物的研发进度，早日为患者带来新的治疗选择。 参考资料： [1]方圆资本生态圈 | 「宝济药业」完成数亿元人民币C轮融资，专注于合成生物学技术平台. Retrieved Jul 19, 2024, from https://mp.weixin.qq.com/s/C-yhlo1lQ7m389nVjDrxVg [2] 大睿生物宣布完成A+轮3500万美元融资，以推进创新性siRNA代谢管线的临床进展及新一代RNA平台的研发. Retrieved Jul 19, 2024, from https://mp.weixin.qq.com/s/yISsFiOoV6ebLEKYl7bAhg [3]夏同生物获得知名上市公司旗下基金投资！. Retrieved Jul 19, 2024, from https://mp.weixin.qq.com/s/UiXiu3CNxIOJ2BqRUq4ZRw [4] 浩博医药AusperBio完成3700万美元A轮融资， 加速变革乙肝治愈疗法. Retrieved July 15 , 2024, from https://cn.ausperbio.com/company.html [5]椎元医学完成数千万元天使轮融资，全力推进椎间盘创新细胞治疗产品开发. Retrieved July 12，2024, From https://mp.weixin.qq.com/s/jximS7NLJmXrF7A3Lzs8Tw [6]普康快讯|普康生物完成一亿元融资. Retrieved July 12，2024, From https://mp.weixin.qq.com/s/QnEtXbXC2ViEqQdc06yUOg [7]跃赛生物再获数千万A+轮融资，干细胞治疗技术持续获得资本认可. Retrieved July 11，2024, From https://mp.weixin.qq.com/s/Tt1BpB3DZ87K3tANNmVayg [8]国投创业领投ASO创新药物研发企业安天圣施. Retrieved July 03，2024, From https://mp.weixin.qq.com/s/xumHVuCp_qMzwOpxfZUx_A [9]慕恩生物完成3亿元C+轮融资，持续推进更多生物创新产业化落地. Retrieved July 1，2024, From https://mp.weixin.qq.com/s/IYpyu_9Snj2rmwzn9vexpQ [10]安邦生技宣布完成A+輪募資，推進ABT-301臨床二期試驗. Retrieved July 1，2024, From https://www.anbogen.com/zh/news-240701.php 内容来源于网络，如有侵权，请联系删除。

TAIPEI, July 1, 2024 /PRNewswire/ -- Anbogen Therapeutics, Inc., a clinical-stage company dedicated to developing breakthrough cancer therapies, has announced the successful closing of a USD 7.3M oversubscribed A+ round financing, which is a direct continuation of the USD 12.5 Million Series A on 1st February, 2024, bringing the total raised to USD 19.8M. The funds from the A+ round will be specifically used to advance the Phase II clinical trial of ABT-301. The financing round was led by KGI Venture Capital and both new and existing investors. The capital raised in the A+ round will primarily be used to support the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer, which accounts for 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors. Previous preclinical studies have repeatedly showed that ABT-301, when combined with immune checkpoint inhibitors, exhibits remarkable synergistic therapeutic effects in various solid tumor models, including subcutaneous xenograft and orthotopic models of colorectal cancer, liver cancer, triple-negative breast cancer, and head and neck cancer. Given these promising results, Anbogen decided to proceed with the A+ round of financing to secure the necessary funds for ABT-301's clinical trial, without impacting the ongoing Phase II development of ABT-101. Leveraging ABT-301's compelling immunomodulatory and synergistic effect combined with PD-1 treatment that Anbogen has observed, we have successfully engaged pharmaceutical companies who will agree to enter PD-1 drug-supply agreement with Anbogen. This collaboration will enable Anbogen to optimize its resource allocation and underscores the strong recognition of both ABT-301 and Anbogen. "We are deeply grateful to our investors for their continued support and confidence in our mission," says Dr. Tsu-An Hsu, CEO of Anbogen Therapeutics. "This funding is crucial for the advancement of ABT-301 combo with immune checkpoint inhibitors treating solid tumors, and it validates our ongoing efforts to bring effective cancer treatments to patients in need." About Anbogen: Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs and is committed to R&D innovations to improve the lives of cancer patients around the world. The company was founded by Dr. Joe Shih, in response to the national science and technology policy. The team has years of experience in new drug development while working at the National Health Research Institutes or biopharma companies. Two of its drugs, ABT-101 for non-small cell lung cancer (NSCLC) with HER2 exon20 insertion mutations and ABT-301(combine with immune checkpoint inhibitors) for metastatic colorectal cancer, are currently in human clinical trials. For more information, please visit Anbogen's official website (). SOURCE Anbogen Therapeutics